Russian Federation: New Registration Rules And Calculation Methodology For Maximum Manufacturer's Sale Prices For Vital And Essential Drugs

Last Updated: 9 October 2015
Article by Anna McDonald

On October 1, 2015, the new versions of the following regulations will come into legal force and effect:

  • The Rules for the state registration and re-registration of maximum sale prices set by pharmaceutical manufacturers for medicines on the list of vital and essential drugs ("EDL") (the EDL Price Registration Rules); and
  • The Methodology for calculating maximum sale prices set by pharmaceutical manufacturers for medicines on the list of vital and essential drugs (the EDL Price Сalculation Methodology).

These new versions of the EDL Price Registration Rules and EDL Price Calculation Methodology were approved by the RF Government Decree No. 979 of September 15, 2015 (the Decree 979).

Decree 979 also clarifies the procedure for the maintenance of the state register of maximum manufacturers' sale prices for medicines (the EDL Price Register).

Decree 979 introduces a large number of changes that are nonetheless mainly supplementary in nature. The new versions of the EDL Price Registration Rules and EDL Price Calculation Methodology detail and formalize many issues concerning calculations of the maximum manufacturer's sale price for an EDL drug (the Maximum Price) and the grounds for changing it. 

Integration of the Eurasian Economic Community (the EAEC) is reflected in the EDL Price Calculation Methodology by setting out special provisions applicable to manufacturers from EAEC states. Some of the rules contain specific provisions applicable to pharmaceutical manufacturers whose products fall within a specific price segment or to manufacturers intending to package medicines in the Russian Federation, etc. 

Acording to the new EDL Price Registration Rules, in order to register or re-register a Maximum Price for a medicine which is on the EDL (the EDL Drug) an applicant will have to provide more information than previously was required. For example, it will be necessary, inter alia, to provide information about the volumes and manufacturer's sale/import price of the EDL Drug in question and a justification for and calculations of the Maximum Price.

The amount of information needed to register the Maximum Price for an EDL Drug that have not yet entered into the Russian market has been considerably expanded. Manufacturers from EAEC member states will be required to provide information about the entity's accounting policy, a breakdown of expenses and costs, documentation of amounts of certain types of expenses, etc. Foreign manufacturers will be required to provide data supporting information about the foreign manufacturer's minimum sale price for such EDL Drug.

A manufacturer from any EAEC member state planning to package an EDL Drug in the Russian Federation, as well as a holder of a marketing authorization for an EDL Drug will be required to submit a similar set of information if there is no registered Maximum Price of the foreign manufacturer for that medicine. 

A number of limits have been set for Maximum Prices. For example, if an application is being filed to register a Maximum Price within the three years from the date the Maximum Price for the same Medicine has been excluded from the EDL Price Register on the basis of an application from the same marketing authorization holder, the new Maximum Price applied for cannot be more than the price previously excluded. The Maximum Price of a generic1 EDL Drug that is not in circulation cannot exceed 80% of the Maximum Price of the reference drug or its analog. The threshold for a biosimilar2 drug is 90%. Limits on the Maximum Price are set for the second and subsequent foreign manufactured generic/biosimilar drugs (5% lower than the most recent registered Maximum Price for the similar drug), and also for cases of a significant decrease from the maximum registered Maximum Price for reference/similar drugs.

In addition, the new version of the EDL Price Registration Rules sets forth in much greater detail the grounds for re-registration of a Maximum Price. Among the reasons for re-registering a Maximum Price are change in prices for raw materials and supplies and overhead expenses, currency exchange rate fluctuations (for a foreign manufacturer's medicines), however, those are taken into account only if certain additional parameters are observed. The grounds for re-registration of Maximum Prices for EDL Drugs in the lower and average price segment of up to and including 500 rubles are set out separately.

A number of amplifying rules are also introduced to the EDL Price Calculation Methodology. The algorithm for recalculating prices for EDL Drugs of the lower and average price segment of up to 500 rubles is set out in detail. Potential limits on the Maximum Price are clarified, for example, for medicines manufactured within an EAEC member state the price cannot be more than the minimum manufacturer's sale price in the countries for which the information about minimum manufacturer's sale prices for medicines (including customs duties and costs) is being provided.

At the same time, the list of those countries has changed. The "manufacturer's country" continues to be indicated in the list, but the vague wording "other countries" has been removed, Germany was deleted from the list, but Hungary was added.

Attention of manufacturers from EAEC member states planning to do primary and/or secondary packaging of Medicines in the Russian Federation is drawn to the fact that the Maximum Price proposed for registration cannot exceed the maximum registered foreign manufacturer's maximum sale price for that medicine. Furthermore, when calculating the Maximum Price for a different quantity of EDL Drug in the secondary (consumer) packaging, the price for a single pharmaceutical unit cannot increase.

The new version of the EDL Price Calculation Methodology generally corresponds to, and is largely consistent with, the new version of the EDL Price Registration Rules.

Manufacturers and developers of essential medicines should take into account that, according to the statements of the governmental officials3, the new versions of the EDL Price Registration Rules and EDL Price Calculation Methodology are only the first stage in making changes to EDL pricing regulation, and other amendments are expected to be adopted by 2016.

Footnotes

1 a medicine that has the same quality and quantity of active ingredients in the same pharmaceutical form as the reference drug and the bioequivalence or therapeutic equivalence of which to the reference drug has been confirmed by the relevant trials. Federal Law No. 61-FZ on the Circulation of Medicines of April 12, 2010.

2 a biological medicine similar in terms of quality, efficacy and safety parameters to the reference biological medicine in the same pharmaceutical form and having an identical mode of administration. Ibid.

3 Interview with Timofey Nizhegorodtsev, Head of the Department for the Protection of Competition in the Social Sphere and Trade of the Federal Antimonopoly Service of Russia - in Russian

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
25 Oct 2018, Other, New York, United States

Once again, Dentons is proud to bring together insurance industry leaders, lawyers and regulators for a full-day examination of the most current issues.

26 Oct 2018, Other, New York, United States

Selling your company may be the most important and complicated transaction of your life. To achieve an optimal outcome, you need to get educated.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions